Notably, Le Roy et al. [56] showed that high expression of OCT3 in colorectal cancer was an independent predictor for resistance to FOLFOX therapy; no such correlation was found in their population for OCT1 or OCT2. Here, SLC22A3 is linked to colorectal cancer.